Meeting
2020 ASCO Virtual Scientific Program
Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.
Authors
Jared Weiss
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
Jared Weiss , Jerome Goldschmidt , Andric Zoran , Konstantin H. Dragnev , Yili Pritchett , Shannon R. Morris , Rajesh K. Malik , Davey B. Daniel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12096)
DOI
10.1200/JCO.2020.38.15_suppl.12096
Abstract #
12096
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Impact of trilaciclib on multilineage chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer: Post-hoc analyses of data from randomized clinical trials.
First Author: Jerome H. Goldschmidt
Poster
2022 ASCO Genitourinary Cancers Symposium
Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).
First Author: Guru P. Sonpavde
Poster
2021 ASCO Annual Meeting
Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP)plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase.
First Author: Maria Rosario García Campelo
Poster
2017 ASCO Annual Meeting
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
First Author: Caio Max S. Rocha Lima